Results 31 to 40 of about 5,923 (201)

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

Mechanisms of Xenogeneic Baboon Platelet Aggregation and Phagocytosis by Porcine Liver Sinusoidal Endothelial Cells [PDF]

, 2012
Background: Baboons receiving xenogeneic livers from wild type and transgenic pigs survive less than 10 days. One of the major issues is the early development of profound thrombocytopenia that results in fatal hemorrhage.
Buhler, Leo, Csizmad, Eva, Deng, Shaoping, Enjyoj, Keiichi, Lee, Kang Mi, Machaidze, Zurab, Markmann, James, Peng, Qiang, Robson, Simon Christopher, Schuetz, Christian, Wei, Lingling, Yeh, Heidi   +11 more
core   +3 more sources

Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice

The Turkish Journal of Gastroenterology, 2020
Background/Aims: To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease. Methods and Material: This study was designed as a controlled, animal, drug safety
Stanko S. Petrovic, Milijana M. Vasiljevska, Slobodan D. Obradovic, Dino K. Tarabar, Radoje B. Doder, Ivana J. Majstorovic, Marijana D. Petrovic, Zvonko M. Magic, Bojana M. Cikota, Nenad J. Perisic, Irina A. Brcerevic, Nebojsa S. Manojlovic, Nemanja K. Rancic   +12 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar   +7 more
doaj   +1 more source

Design of termo-sensitive molecularly imprinted polymers(MIP) and in vitro evaluation of controlled release of Eptifibatide drug [PDF]

شیمی کاربردی روز
In this research, a nano polymer was fabricated via the molecular imprinted polymer (MINP) method to transport and control the release of the drug eptifibatide.
Sharif Kaamyabi, Negar Karimi Hajishoreh, Abolfazl Akbarzadeh   +2 more
doaj   +1 more source

Cryo-EM structures of full-length integrin αIIbβ3 in native lipids

Nature Communications, 2023
Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation).
Brian D. Adair, Jian-Ping Xiong, Mark Yeager, M. Amin Arnaout   +3 more
doaj   +1 more source

Integrins as therapeutic targets: lessons and opportunities. [PDF]

, 2010
The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and ...
A Artoni, A Carter, A Etzioni, A Kato, A Loughman, A McDowall, A Qu, A Robinson, A Salas, AD Ricart, AJ Ablooglu, AL Muranyi, AM Weljie, AR Reynolds, AW Partridge, B Furie, BG Feagan, BG Petrich, BP Feuston, BS Coller, C Delbaldo, C Kummer, C Kummer, C Leonardi, C Lu, C Ng, C Rosano, C Warnke, C Xie, CH Polman, CJ Avraamides, CL Leonardi, CL Tofteng, CS Tan, CS Yoon, D Chua, D Cox, D Cox, D Larkin, D Potin, DA Calderwood, DA Calderwood, DA Chudakova, DA Reardon, Dermot Cox, DJ White, DP Chew, DR Phillips, DS Dodd, DS Harburger, E Bernard, E Havrdova, E Manevich, E Ruoslahti, EO Major, FC Gushiken, FE Fleming, G Weitz-Schmidt, GA Caputo, GM D'Abaco, GPA Rice, H Jin, H Yin, H Zhang, H-J Lee, I Ahrens, J Bennett, J Kallen, J Kalra, J Lim, J Morova, J Takagi, J Takagi, J Tamkun, JA Askari, JA Nemeth, JC O'Shea, JE Frampton, JE Smith-Garvin, JP Ortonne, JP Xiong, JP Xiong, JR Fitzgerald, JR Fitzgerald, JR Morgan, JW Tilley, K Aylward, K Peter, K Peter, K Welzenbach, K Yao, K Yuki, KB Gordon, KB Reddy, KL Graham, KL Graham, KL Schornberg, KL Wegener, KR Legate, KV Vijayan, L Dubertret, L Steinman, L Xudong, LM Kenny, M Brennan, M Champe, M Egbertson, M Kim, M Lebwohl, M Martchenko, M Moser, M Raab, M Rosenthal, M Shimaoka, M Shimaoka, M Shimaoka, M Shimaoka, MA Arnaout, Marian Brennan, MC Joseph, ME Cianfrocca, MG Murphy, MN Younes, MP Bonaca, MP Brennan, MP Crump, N Laurens, Niamh Moran, NS Nicholson, O Vinogradova, O Vinogradova, P Hersey, P Koistinen, PA Calabresi, PC McDonald, PE Hughes, PL Stewart, QY Liu, R Anders, R Axelsson, R Blue, R Curtin, R Evans, R Gonzalez-Amaro, R Pytela, R Silva, R Stragies, R Stupp, RA Rudick, RH Aster, RJ Davenport, RJ Davenport, RM Scarborough, RO Hynes, RP Dassanayake, S Honda, S Honda, S Kim, S Kim, S Li, S Liu, S Moschos, S O'Neill, S Wattanasin, SH Watterson, SJ Hyduk, SJ Monkley, SJ Moschos, SJ Shattil, SM Keating, SM Weis, SR Barthel, SR Targan, T Dileepan, T Kwok, T Weller, T Xiao, TA Kelly, TA Yednock, TC Sroka, TE O'Toole, TE Spencer, TJ MacDonald, TM Brophy, TR Gadek, UP Naik, VA Umans, W Humphrey, W Jia, W Neidhart, W Wang, W Yang, X Sewald, Y Aga, Y Funahashi, Y Gong, Y Li, Y Wang, YF Li, YQ Ma   +199 more
core   +1 more source

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent.
Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli, Anita Deswal, Susan Halli Demeter, Gregory Durm, Anecita Fadol, Alessandra Ferrajoli, Michael G. Fradley, Joerg Herrmann, Borja Ibanez, Sue Koob, Bogda Koczwara, Kasey J. Leger, Jennifer E. Liu, Teresa López‐Fernández, Alexander R. Lyon, N. G. Choon Ta, John Teerlink, Eric H. Yang, Susan Dent, Daniel Lenihan   +22 more
wiley   +1 more source

Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial [PDF]

, 1999
BACKGROUND: The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.
Alberts, M.J., Berdan, L.G. (Lisa), Califf, R.M. (Robert), Deckers, J.W. (Jaap), Graffagnino, C. (Carmen), Granger, C.B. (Christopher), Harrington, R.A. (Robert Alex), Laskowitz, D.T., Lincoff, A.M. (Michael), MacAulay, C.M., Mahaffey, K.W. (Kenneth), Miller, J.M., Simoons, M.L. (Maarten), Sloan, M.A. (Michael), Topol, E.J. (Eric)   +14 more
core   +1 more source